Resources from the same session
2449 - Conversion rate in locally advanced pancreatic cancer (LAPC) after nab-Paclitaxel/Gemcitabine- or FOLFIRINOX-based induction chemotherapy (NEOLAP) - Final Results of a multicenter randomised Phase 2 AIO trial -
Presenter: Volker Kunzmann
Session: Proffered Paper 1 – Gastrointestinal tumours, non-colorectal
Resources:
Abstract
Slides
Webcast
6572 - CheckMate 459: A Randomized, Multi-Center Phase 3 Study of Nivolumab (NIVO) vs Sorafenib (SOR) as First-Line (1L) Treatment in Patients (pts) With Advanced Hepatocellular Carcinoma (aHCC)
Presenter: Thomas Yau
Session: Proffered Paper 1 – Gastrointestinal tumours, non-colorectal
Resources:
Abstract
3502 - Randomised Efficacy and Safety Results For Atezolizumab (Atezo) + Bevacizumab (Bev) in Patients (pts) With Previously Untreated, Unresectable Hepatocellular Carcinoma (HCC)
Presenter: Michael Lee
Session: Proffered Paper 1 – Gastrointestinal tumours, non-colorectal
Resources:
Abstract
Slides
Webcast
Proffered Paper 1 – Gastrointestinal tumours, non-colorectal - Invited Discussant LBA38_PR and LBA39
Presenter: Arndt Vogel
Session: Proffered Paper 1 – Gastrointestinal tumours, non-colorectal
Resources:
Slides
Webcast
2550 - FIGHT-202: a phase 2 study of pemigatinib in patients (pts) with previously treated locally advanced or metastatic cholangiocarcinoma (CCA)
Presenter: Arndt Vogel
Session: Proffered Paper 1 – Gastrointestinal tumours, non-colorectal
Resources:
Abstract
Slides
Webcast